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Phospholipase D (PLD) has been suggested to mediate epidermal growth factor (EGF) signaling.
However, the molecular mechanism of EGF-induced PLD activation has not yet been elucidated. We
investigated the importance of the phosphorylation and compartmentalization of PLD1 in EGF
signaling. EGF treatment of COS-7 cells transiently expressing PLD1 stimulated PLD1 activity and
induced PLD1 phosphorylation. The EGF-induced phosphorylation of threonine147 was completely
blocked and the activity of PLD1 attenuated by point mutations (S2A/T147A/S561A) of PLD1
phosphorylation sites. The expression of a dominant negative PKC mutant by adenovirus-mediated
gene transfer greatly inhibited the phosphorylation and activation of PLD1 induced by EGF in
PLD1-transfected COS-7 cells. EGF-induced PLD1 phosphorylation occurred primarily in the caveo-
lin-enriched membrane (CEM) fraction, and the kinetics of PLD1 phosphorylation in the CEM were
strongly correlated with PLD1 phosphorylation in the total membrane. Interestingly, EGF-induced
PLD1 phosphorylation and activation and the coimmunoprecipitation of PLD1 with caveolin-1 and
the EGF receptor in the CEM were significantly attenuated in the palmitoylation-deficient C240S/
C241S mutant, which did not localize to the CEM. Immunocytochemical analysis revealed that
wild-type PLD1 colocalized with caveolin-1 and the EGF receptor and that phosphorylated PLD1 was
localized exclusively in the plasma membrane, although some PLD1 was also detected in vesicular
structures. Transfection of wild-type PLD1 but not of C240S/C241S mutant increased EGF-induced
raf-1 translocation to the CEM and ERK phosphorylation. This study shows, for the first time, that
EGF-induced PLD1 phosphorylation and activation occur in the CEM and that the correct localization
of PLD1 to the CEM via palmitoylation is critical for EGF signaling.
INTRODUCTION
Epidermal growth factor (EGF) binds to a specific cell-surface
receptor (EGF receptor, EGFR), stimulating cell growth and
other important physiological functions (Carpenter and Cohen,
1990; Ullrich and Schlessinger, 1990). The EGF-induced activa-
tion of the EGFR leads to phosphatidylcholine hydrolysis,
which increases phosphatidic acid (PA) levels (Cook and
Wakelam, 1992; Kaszkin et al., 1992; Yeo and Exton, 1995). PA
seems to be a potential second messenger (English et al., 1996)
and has been implicated in a variety of cellular physiological
processes, such as proliferation (Fukami and Takenawa, 1992;
English et al., 1996), endocytosis (Shen et al., 2001), exocytosis
(Cockcroft, 1992; Way et al., 2000), and cytoskeletal rearrange-
ment (Ha and Exton, 1993; Honda et al., 1999). Therefore,
phospholipase D (PLD), which is a phosphatidylcholine-hy-
drolyzing enzyme and generates PA, may be an important
mediator of EGF signaling.
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We reported previously that platelet-derived growth fac-
tor–induced activation of PLD might be an event down-
stream of the primary stimulation of PLC-1 and PKC (Lee
et al., 1994). It has since been reported that in Swiss 3T3 cells,
the stimulation of PLD by EGF requires PKC activation (Yeo
and Exton, 1995). In contrast, it has also been reported that
EGF-induced PLD activation occurs independently of PKC
in Swiss 3T3cells and in A431 cells (Cook and Wakelam,
1992). Thus, the requirement for PKC in EGF-induced PLD
activation remains controversial. Two isozymes of mamma-
lian PLD, PLD1 and PLD2, have been cloned (Hammond et
al., 1995; Colley et al., 1997; Park et al., 1997; Lopez et al.,
1998). PLD1 is known to be regulated by PKC in vivo.
Recently, it was reported that PLD1 PIM87 mutant, which is
unresponsive to PKC, could not be activated in vivo by
treatment with phorbol 12-myristate 13-acetate (PMA) and
carbachol (Zhang et al., 1999). After cells were treated with
PMA, PLD1 was found to associate with PKC and to be
multiply phosphorylated (Lee et al., 1997; Kim et al., 1999).
Recently, both PLD1 and PLD2 were found to be activated
by EGF stimulation (Slaaby et al., 1998), and this study also
found that the EGFR is implicated in the phosphorylation of
tyrosine 11 of PLD2. However, the molecular mechanism of
PLD1 activation by EGF stimulation remains unknown.
PLD1 has been identified in diverse subcellular or-
ganelles, including the endoplasmic reticulum (ER), Golgi,
endosomes, lysosomes, and plasma membrane (Brown et al.,
1998; Jones et al., 1999; Kim et al., 1999; Roth et al., 1999; Toda
et al., 1999). ADP-ribosylation factor (ARF), which is a well-
known activator of PLD1, is required for many vesicular
processes between the Golgi, ER, and plasma membranes
(Jones et al., 1999). Conversely, PKC-regulated PLD1 was
found to be restricted to the caveolin-enriched microdo-
mains within the plasma membrane (Kim Y et al., 2000).
Thus, PLD1 may be differentially regulated at different lo-
cations by different activators. However, the intracellular
location of EGF-stimulated PLD1 remains unknown.
Caveolae are plasma membrane invaginations rich in gly-
cosphingolipids and cholesterol (Anderson, 1998). Many in-
tracellular signaling molecules, including G subunits, Ha-
Ras, endothelial nitric oxide synthase, and the Src family of
tyrosine kinases, are localized to these microdomains (Oka-
moto et al., 1998). Many acylated proteins are known to be
localized to caveolae; accordingly, it has been suggested that
posttranslational modifications of lipids, such as myristoyl-
ation and palmitoylation, are required and play an impor-
tant part in the molecular mechanism of localization to the
caveolae (Okamoto et al., 1998). The growth factor–induced
Ras/Raf-1 and MAP kinase pathways are two well-under-
stood processes that occur in caveolae (Mineo et al., 1996; Liu
et al., 1997). Moreover, the entire pathway from platelet-
derived growth factor stimulation to MAP kinase activation
is known to function in isolated caveolae (Liu et al., 1997).
Although PLD1 is known to be localized to caveolae (Kim et
al., 1999), it remains to be determined how PLD1 can be
localized to caveolae and whether the regulatory machinery
of PLD1 activation by EGF stimulation is also localized in
caveolae.
In this study, we investigated these issues concerning the
molecular mechanism and subcellular compartmentaliza-
tion of EGF-induced PLD1 activation. For the first time, we
show that PKC-dependent phosphorylation is required for
EGF-induced PLD1 activation and that the correct localiza-




Phenylmethylsulfonylfluoride, leupeptin, and aprotinin were ob-
tained from Roche Molecular Biochemicals; paraformaldehyde and
anti-actin antibody from Sigma (St. Louis, MO); [3H]palmitic acid
and [32P]orthophosphate from Dupont NEN (Boston, MA);
[3H]myristic acid and the chemiluminescence kit (ECL system) from
Amersham International (Buckinghamshire, U.K.); Silica Gel 60 TLC
plates from Merck (Darmstadt, Germany); immobilized protein A
and rhodamine-conjugated anti-mouse antibody from Pierce (Rock-
ford, IL); DMEM and LipofectAmine from Gibco-BRL (Grand Is-
land, NY); fetal bovine serum from PAA Laboratories, Inc. (Parker
Ford, PA); and horseradish peroxidase–conjugated goat anti-rabbit
IgG or anti-mouse IgG, IgM, and IgA from Kirkegaard and Perry
Laboratories, Inc. (Gaithersburg, MD). The antibody against the
C-terminal region of PLD1 was made and purified as described
previously (Lee et al., 1997). Anti-PKC monoclonal antibody
(mAb), anti-PKC mAb, anti-BiP/GRP78 mAb, and anti-EGFR poly-
clonal antibody were purchased from Transduction Laboratories
(Lexington, KY). Anti-phospho-Erk mAb was from New England
Biolabs (Beverly, MA), anti-Raf-1 polyclonal antibody from Upstate
Biotechnology (Lake Placid, NY), and anti-caveolin-1 polyclonal
antibody from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell Culture
COS-7 cells were cultured at 37°C in a humidified 5% CO2 atmo-
sphere in high-glucose DMEM supplemented with 10% heat-inac-
tivated fetal bovine serum.
In Vivo Assay of PLD
Transfections and assays of PLD were performed as previously
described (Kim et al., 1999). Briefly, PLD1 was transiently overex-
pressed at 5  105 cells per 60-mm dish. Transfection was per-
formed with LipofectAmine according to the manufacturer’s in-
structions. Twenty-four hours after transfection, the cells were
starved for 24 h and then incubated with 5 Ci [3H]myristic acid for
3 h. The cells were then treated with EGF in the presence of 1.5%
ethanol, as described in the figure legends. Lipids were extracted
and separated by Silica Gel 60 TLC (chloroform:methanol:acetic
acid, 90:10:10 by volume). A Fuji BAS-2000 image analyzer (Fuji
Film, Tokyo, Japan) was used to determine the quantities of labeled
phosphatidylethanol and total lipids.
Infection of COS-7 Cells with Dominant Negative
PKC Adenoviruses
The adenovirus expression vector for dominant negative (DN)-
PKC (DN-PKC AdV) or DN-PKC (DN-PKC AdV) has been
described previously (Ohba et al., 1998; Kuroki et al. 1999). Three
hours after the transfection, COS-7 cells were infected with DN-
PKC AdV of DN-PKC AdV for 6 h in DMEM supplemented with
10% fetal bovine serum. After the virus was removed, the cells were
incubated for an additional 24 h in DMEM supplemented with 10%
fetal bovine serum and reincubated for 24 h in serum-free DMEM.
Construction of Expression Plasmids
The splice-overlap extension method (Ho et al., 1989) was used to
generate the C240S/C241S mutant using the following oligonucle-
otides: forward primer, 5-CCGGAATTCACATGGCAAGTTAA-
GAG-3/reverse primer, 5-CCATGGCCACTGCTATTCACAC-3
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and forward primer, 5-GTGTGAATAGCAGTGGCCATGG-3/re-
verse primer, 5-CCGGAATTCTTTGTCTACAAGAAGGACG-3.
Next, the C240S/C241S mutant was amplified using forward primer
5-CCGGAATTCACATGGCAAGTTAAGAG-3 and reverse primer
5-CCGGAATTCTTTGTCTACAAGAAGGACG-3. The EcoRI frag-
ment of the PCR product was then exchanged with the EcoRI
fragment of the wild-type (WT) PLD1 cDNA, and the whole PLD1
C240S/C240S cDNA was cloned into the pCDNA3.1 vector. The
mutations were verified by sequence analysis.
Immunoprecipitation and Immunoblot Analysis
of PLD1
Immunoprecipitation and immunoblot analysis were performed as
described previously (Kim Y, et al., 2000). Briefly, the cells were
lysed in 1 ml of lysis buffer (10 mM Tris, pH 7.5, 1 mM EDTA, 0.5
mM EGTA, 10 mM NaCl, 1% Triton X-100, and 1% sodium cholate)
containing protease inhibitors (0.5 mM PMSF, 1 g/ml leupeptin,
and 5 g/ml aprotinin) and phosphatase inhibitors (30 mM NaF, 1
mM Na3VO4, 30 mM Na4O7P2). After centrifugation (150,000 g for
30 min), equal amounts of soluble extract were incubated with 2 g
of anti-PLD antibody precoupled to immobilized protein A agarose
resin. The immunoprecipitated proteins were then separated in
6–16% gradient SDS-polyacrylamide gels. Anti-PLD antibody, anti-
EGFR mAb, anti-caveolin-1 polyclonal antibody, or the culture su-
pernatant of a hybridoma cell line secreting anti-phospho-PLD1 was
used as primary antibody.
Labeling of COS-7 Cells with [3H]palmitate
Forty-three hours after transfection, COS-7 cells were washed with
serum-free DMEM and then incubated with 1 mCi/ml [9,10-
3H]palmitic acid for 5 h at 37°C. Cells were then washed in ice-cold
phosphate-buffered saline (PBS), harvested by scraping, and lysed
in lysis buffer (10 mM Tris, pH 7.5, 1 mM EDTA, 0.5 mM EGTA, 10
mM NaCl, 1% Triton X-100, and 1% sodium cholate) containing
protease inhibitors (0.5 mM PMSF, 1 g/ml leupeptin, and 5 g/ml
aprotinin). The cell lysates were then clarified by centrifugation and
immunoprecipitated with 2 g of anti-PLD antibody precoupled to
protein A agarose. Immunoprecipitates were washed 5 times with
lysis buffer, eluted with 5  nonreducing Laemmli sample buffer by
boiling for 6 min, subjected to SDS-PAGE, and then transferred to a
nitrocellulose membrane. The PLD1 band was excised, and radio-
activity was monitored by Cerenkov counting.
Isolation of Caveolin-enriched Membranes
Caveolin-enriched membranes (CEMs) were prepared as previously
described (Kim et al., 1999), with some modification. In brief, COS-7
cells overexpressing PLD1 in a 100-mm dish were starved for 24 h
and then treated with 100 nM of EGF for 0.5 min. The cells were
then washed with PBS and scraped into 2 ml of 500 mM sodium
carbonate, pH 11.0. The cell suspension was then homogenized with
a Dounce homogenizer and a Polytron tissue grinder and lysed by
sonication. The lysed homogenate was adjusted to 40% sucrose by
adding 80% sucrose in MBS buffer (25 mM MES-NaOH, pH 6.5, and
150 mM NaCl) and placed in the bottom of a centrifuge tube. Four
milliliters of 30% and then 4 ml of 5% sucrose in MBS buffer were
layered on top. The sample was centrifuged at 100,000  g for 6 h,
and twelve 1-ml fractions were collected from the top of the tube.
Immunocytochemical Analysis
COS-7 cells were grown on coverslips and were cotransfected with
pGFP-PLD1 WT or pGFP-PLD1 C240S/C241S mutant and with
pDsRed1-c1-caveolin-1 (RFP-caveolin-1) or pDsRed1-C1-EGFR
(RFP-EGFR). The cells were fixed in 4% (wt/vol) paraformaldehyde
for 30 min at 37°C, washed with PBS, and mounted on slides. GFP-
or RFP-tagged proteins were visualized by confocal laser scanning
microscopy (Zeiss, Oberkochen, Germany) using appropriate filters.
To detect the localization of phospho-PLD1, after stimulation with
100 nM of EGF for 0.5 min, the cells were fixed in 4% (wt/vol)
paraformaldehyde for 30 min at 37°C, washed with PBS, and incu-
bated in blocking buffer (1% goat serum in PBS containing 0.2%
Triton X-100) at 4°C for 1 h. Subsequently, the cells were incubated
with anti-phospho-PLD1 antibody overnight at 4°C. After three
washes with PBS containing 0.05% Triton X-100, the cells were
incubated with rhodamine-conjugated anti-mouse antibody for 90
min. After three additional washes with PBS containing 0.05% Tri-
ton X-100, the cells were mounted and visualized by confocal laser
scanning microscopy (Zeiss).
Measurement of In Vitro PLD Activity
PLD activity was measured by choline release from phosphatidyl-
choline, as described previously (Kim et al., 1999)
RESULTS
EGF Induces the Activation and Phosphorylation
of PLD1
To investigate the molecular mechanism of PLD1 activation by
EGF and especially the involvement of PKC, we used COS-7
cells transfected with rat PLD1. PLD activity was determined
by use of the unique ability of PLD1 to produce phosphati-
dylethanol in the presence of ethanol. To access the dose re-
sponse of EGF on PLD1, we monitored the formation of phos-
phatidylethanol at 1-min intervals after adding various doses
of EGF. These treatments increased PLD1 activity at nanomolar
EGF concentrations, and a saturated response was obtained
with 100 nM of EGF (Figure 1A). To compare the kinetics of
phosphorylation and activation, we monitored the formation
of phosphatidylethanol at 1-min intervals by adding alcohol
separately after EGF stimulation. The temporal response of
PLD1 to EGF was very rapid: its activity peaked within only
30 s (with alcohol present from 0 to 1 min after the EGF
stimulation), after which its activity decreased (Figure 1B).
Recently, we reported that PLD1 undergoes phosphorylation
at multiple sites, including serine2, threonine147, and
serine561, on PMA stimulation (Kim et al., 1999). We also found
that EGF induces multisite phosphorylation of PLD1, including
serine2, threonine147, and serine561, and that the pattern of the
PLD1 phosphopeptide map from EGF-stimulated cells was
very similar to that obtained from PMA-stimulated cells (data
not shown). Of the many sites phosphorylated, phosphoryla-
tion at threonine147 is one of the most easily monitored by use
of the anti-phospho-threonine147 antibody (Kim Y et al., 2000).
Maximal phosphorylation of threonine147 was observed at an
EGF concentration of 100 nM (Figure 2A). The kinetics of the
activation and the phosphorylation were very similar, because
the phosphorylation also peaked within 30 s and then gradu-
ally diminished (Figure 2B). Thus, phosphorylation and acti-
vation seem to occur concurrently after EGF stimulation.
Phosphorylation of PLD1 Is Required for EGF-
induced PLD1 Activation
We previously identified serine2, threonine147, and
serine561 as direct phosphorylation sites by PKC (21). Triple
mutation (S2A/T147A/S561A) of these sites greatly attenu-
ated PMA-induced PLD1 activity compared with WT PLD1.
Therefore, we also examined the effect of triple mutation on
EGF-induced PLD1 activity. As shown in Figure 3A, we
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confirmed that triple mutation completely blocked basal and
EGF-induced threonine147 phosphorylation. The EGF-in-
duced activity of triple-mutant PLD1 was significantly re-
duced compared with WT PLD1 (Figure 3B). This suggests
that PKC-mediated phosphorylation is a major activation
mechanism for EGF-induced PLD1 activity.
Effect of Dominant Negative PKC on EGF-induced
PLD1 Phosphorylation and Activation
To investigate which isozyme of PKC is involved in EGF-
induced PLD1 phosphorylation and activation and whether
PLD1 is regulated in a phosphorylation-dependent manner,
dominant negative (DN) types of PKC and PKC were
expressed with adenovirus expression vector. Infection of
COS-7 cells with DN-PKC or DN-PKC adenovirus re-
sulted in dose-dependent increases in the amounts of PKC
or PKC as assessed by immunoblot analysis. The amounts
of PKC and PKC proteins in cells infected at a multiplicity
of infection (MOI) (pfu/cell) of 20 were 20 times that of
endogenous PKC and PKC proteins, respectively (Figure
4A). The endogenous level of PKC protein was unchanged
by infection with DN-PKC adenovirus and vice versa. In-
terestingly, the expression of DN-PKC inhibited the EGF-
induced PLD1 phosphorylation (Figure 4B) and the EGF-
induced PLD1 activation (Figure 4C), whereas the
expression of DN-PKC potentiated the EGF-induced PLD1
phosphorylation (Figure 4B) and the EGF-induced PLD1
activation (Figure 4C). These data suggest that PKC is a
positive regulator of EGF-induced PLD1 activity and PKC
is a negative regulator of the EGFR/PKC/PLD1 pathway
and that PKC-mediated phosphorylation is a major activa-
tion mechanism of EGF-induced PLD1 signaling.
PLD1 in CEM Becomes Phosphorylated on EGF
Treatment
The PMA-induced phosphorylation of PLD1 by PKC was
previously observed to occur primarily in the caveolin-en-
Figure 1. Concentration and time-dependent activation of PLD1
by EGF in COS-7 cells. COS-7 cells (2.5  105) were transfected with
1 g of vector (pCDNA3.1) alone or with rat PLD1. Twenty-four
hours after transfection, the cells were starved for 24 h before being
incubated with [ 3H]myristic acid for 3 h. (A) Cells were treated with
various concentrations of EGF for 1 min in the presence of 1.5%
ethanol. PLD activity was determined by measuring the formation
of phosphatidylethanol (PEt) relative to total lipids. (B) To compare
the kinetics of activation and phosphorylation, cells were stimulated
with 100 nM of EGF, 1.5% ethanol was added at different times for
1-min intervals, and the lipids were then extracted for analysis.
Time 0 min indicates incubation in the presence of 1.5% ethanol but
no EGF. The other times mentioned indicate that the EGF was
added at time 0 and that the ethanol was added 30 s before the time
mentioned, i.e., 20 min means that the EGF was added at 0 min and
that the cells were exposed to ethanol for 1 min between 19.5 min
and 20.5 min. Inset, the PLD1 activity presented was calculated by
subtracting the values obtained for cells transfected with vector
alone (MOCK) from the values of cells overexpressing PLD1. Bars
represent the range of duplicate determinations. The data shown are
representative of three separate experiments.
Figure 2. EGF-dependent phosphorylation of PLD1 in COS-7 cells.
(A) COS-7 cells overexpressing PLD1 were treated with various con-
centrations of EGF for 1 min. PLD1 was immunoprecipitated from 1
mg of cell lysate with anti-PLD antibody and then subjected to immu-
noblot analysis with anti-phospho-PLD1 or anti-PLD antibody. (B)
Quiescent COS-7 cells overexpressing PLD1 were stimulated with 100
nM of EGF for the indicated times, followed by immunoprecipitation
and immunoblot analysis as described above. The data shown are
representative of three independent experiments.
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riched, low-density membrane fraction, and therefore, the
compartmentalization of PLD1 regulation was suggested
(Kim Y et al., 2000). To pinpoint the site of EGFR-mediated
PLD1 phosphorylation, we fractionated COS-7 cells and
then monitored the phosphorylation of threonine147 in
PLD1. A basal level of threonine147 phosphorylation was
detected in the CEM, which was found to increase after EGF
treatment (Figure 5A). Moreover, the EGF-induced phos-
phorylation of PLD1 in the CEM exhibited the same time
course as that observed in whole cells, that is, the level of
phosphorylation peaked within 30 s and then decreased
gradually to the basal level (Figure 5B). We also observed
the translocation of PKC to the CEM in response to EGF
treatment. PKC was weakly detectable in the CEM before
EGF treatment, but the amount of PKC in the CEM clearly
increased within 30 s of EGF treatment and then disap-
peared, suggesting that the temporal nature of PLD1 phos-
Figure 3. EGF-induced PLD1 activity is reduced in cells carrying a
triple mutation of phosphorylation sites. (A) COS-7 cells were trans-
fected with WT or triple-mutant (TM) PLD1. Twenty-four hours
after transfection, cells were starved for 24 h and then treated with
100 nM EGF for 0.5 min. PLD1 was immunoprecipitated from 2 mg
of cell lysates. The proteins were separated by 8% SDS-PAGE and
subjected to immunoblot analysis with anti-PLD or anti-phospho-
PLD1 antibody. These data are representative of three independent
experiments. (B) [3H]myristic acid–loaded COS-7 cells were treated
with 100 nM EGF and 1.5% ethanol for 0.5 min. The PLD activity
was determined by measuring the formation of phosphatidyletha-
nol (PEt) relative to total lipids. The data are representative of three
independent experiments.
Figure 4. Effect of DN-PKC and DN-PKC on EGF-induced PLD1
phosphorylation and activation. (A) COS-7 cells were infected with DN-
PKCAdV or DN-PKCAdV for 6 h at different MOIs, as indicated. Cell
lysates (20 g) were separated by 8% SDS-PAGE, transferred to a nitro-
cellulose membrane, and analyzed by Western blot using anti-PKC,
anti-PKC, or anti-actin antibody. (B) COS-7 cells were transfected with
WT PLD1. After 1 h, cells were infected with DN-PKCAdV or DN-PKC
AdV for 6 h at an MOI of 20. Twenty-four hours after infection, the cells
were starved for 24 h and then treated with 100 nM EGF for 0.5 min. Cell
lysates were immunoprecipitated with anti-PLD antibody, and the result-
ing precipitates were subjected to SDS-PAGE and quantified by use of
anti-PLD or anti-phospho-PLD1 antibody. Data are representative of three
separate experiments. (C) COS-7 cells were transfected with vector or WT
PLD1. After 1 h, cells were infected with DN-PKC AdV or DN-PKC
AdV (MOI  20 pfu/cell) for 6 h. After 43 h, cells were labeled with
[3H]myristic acid (5Ci/ml) for 3 h and then treated with 100 nM EGF for
0.5 min in the presence of 1.5% ethanol (vol/vol). The data shown repre-
sent mean SD values from three independent experiments performed in
duplicate. PEt, phosphatidylethanol.
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phorylation and PKC translocation to the CEM are very
similar. Interestingly, we also found the translocation of
PKC to the CEM in response to EGF treatment (Figure 5A).
Because the expression of DN-PKC potentiated EGF-in-
duced PLD1 phosphorylation (Figure 4B) and EGF-induced
PLD1 activation (Figure 4C), these results suggest that the
translocation of PKC to the CEM induced by EGF treatment
may contribute to the negative regulation of EGF-induced
PLD1 activation.
Palmitoylation Is Critical for the Localization of
PLD1 to the CEM
Lipid modifications of signaling molecules often facilitate
their correct targeting to caveolae (Okamoto et al., 1998).
Palmitoylation of PLD1 was recently observed, and the site
of the fatty acylation was determined as cysteine240 and
cysteine241 (Sugars et al., 1999). Consistent with this report,
we found a lack of palmitoylation in the C240S/C241S mu-
tant PLD1 (Figure 6A). To confirm whether palmitoylation
of PLD1 is essential for the localization of PLD1 to the CEM,
we examined the localization pattern of PLD1 in the C240S/
C241S mutant. WT PLD1 was found to be located in the
CEM and in the non-CEM fraction, but strikingly, most of
the PLD1, which was expected to be CEM-located, remained
in the non-CEM fraction in the mutant and was not cofrac-
tionated with the EGFR and caveolin-1 (Figure 6B). It has
been reported previously that the EGFR is located in caveo-
lae (Okamoto et al., 1998), and we also found that the EGFR
is localized primarily in the CEM (Figure 6B). To exclude the
possibility that the amount of caveolin-1 and EGFR in the
CEM is changed by the transfection of the WT or the C240S/
C241S mutant of PLD1, we examined the amounts of caveo-
lin-1 and EGFR in the CEM fraction. However, no differ-
ences in the amounts of caveolin-1 or EGFR were found in
the CEM of the WT- or C240S/C241S mutant-transfected
cells (Figures 6B and 10). To determine whether palmitoyl-
ation of PLD1 is required for PLD1 localization to the CEM,
GFP-PLD1 WT and GFP-PLD1 C240S/C241S were tran-
siently coexpressed with RFP-caveolin-1 and RFP-EGFR in
COS-7 cells. As shown in Figure 6C, GFP-PLD1 WT was
generally present in the plasma membrane and on punctate
structures in the cytoplasm. Similarly, caveolin-1 was local-
ized in the plasma membrane and on punctate structures
through the cytoplasm, indicating that PLD1 WT colocalized
with caveolin-1. However, the GFP-C240S/C241S mutant
showed a different distribution, because it was localized
primarily to the plasma membrane and displayed a scat-
tered distribution through the cytoplasm (Figure 6C). In
addition, this mutant did not seem to colocalize with caveo-
lin-1. Similarly, GFP-PLD1 WT colocalized with EGFR in the
plasma membrane and on punctate structures inside cells,
but the GFP-PLD1 C240S/C241S mutant did not seem to
colocalize with EGFR (Figure 6D). These results suggest that
palmitoylation of PLD1 is essentially required for PLD1
localization to the CEM and for colocalization with caveo-
lin-1 and the EGFR. We also analyzed the distribution of
PLD1 WT and C240S/C241S mutant by subcellular fraction-
ation (Figure 6E). Although the GFP-C240S/C241S mutant
displayed a scattered distribution through the cytoplasm,
under conditions in which the majority of PLD1 WT was
recovered with the membrane fraction, C240S/C241S mu-
tant was also recovered with the membrane fraction, sug-
gesting that C240S/C241S mutant was still localized to the
membrane. From these results, we concluded that palmi-
toylation of PLD1 contributes to its localization to the CEM,
but it cannot account completely for the localization on
membranes in general.
Complex Formation between PLD1 and Caveolin-1
and the EGFR within the CEM
As is shown by Figure 7, the EGFR and caveolin-1 were
coimmunoprecipitated with PLD1 WT but not with PLD1
C240S/C241S in the CEM fraction, which suggests complex
formation between PLD1, caveolin-1, and the EGFR within
the CEM. The amount of each molecule in the immune
complexes was not substantially changed by EGF treatment.
The observation that PLD1 is coimmunoprecipitated with
Figure 5. EGF-induced phosphorylation of PLD1 occurs in the
CEM fraction. (A) After transfection with PLD1 and serum starva-
tion, the COS-7 cells were incubated in the absence or presence of
100 nM EGF for 0.5 min. CEMs were prepared by sucrose density-
gradient centrifugation. Twenty-five microliters of each fraction was
subjected to 6–16% gradient SDS-PAGE followed by immunoblot
analysis with anti-PLD, anti-phospho-PLD1, anti-PKC, anti-PKC,
and anti-caveolin-1 antibodies. (B) COS-7 cells overexpressing PLD1
were stimulated with 100 nM of EGF for the indicated times or with
100 nM of PMA as a control, and this was followed by sucrose
density gradient centrifugation to prepare the CEM fraction. CEM
lysates were immunoprecipitated (I.P.) with anti-PLD antibody, and
the resulting precipitates were subjected to SDS-PAGE and quanti-
fied by use of anti-PLD or anti-phospho-PLD1 antibody. Equal
volumes of fraction 5 were separated by 6–16% gradient SDS-
PAGE, followed by immunoblot analysis with anti-PKC or anti-
caveolin-1 antibody. The data shown are representative of three
separate experiments.
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caveolin-1 and the EGFR can also be explained by the fact
that these proteins are colocalized to membrane domains
that are insoluble in nonionic detergent rather than by the
formation of a complex between these proteins. To exclude
this possibility, we used Nonidet P-40, deoxycholate, and
-octylglucopyranoside to extract the CEM proteins. Before
these detergents were used, caveolin-1, PLD1, and the EGFR
were detected in the 150,000  g pellet of the CEM fraction,
but after these detergents were used, these proteins were
detected in the 150,000  g supernatant of the CEM fraction
(data not shown). This result suggests that palmitoylation of
PLD1 is essentially required for its localization to the CEM,
in which PLD1 forms a molecular complex with the EGFR
and caveolin-1.
Palmitoylation of PLD1 Is Critical for Its
Phosphorylation and Activation by EGF
The palmitoylation-deficient mutant proved to be a useful
tool in the study of the importance of the localization of
PLD1 to the CEM. EGF-induced phosphorylation of C240S/
C241S was remarkably reduced compared with the WT (Fig-
ure 8A), and EGF-induced PLD1 activity was also attenu-
ated in this mutant (Figure 8B). To eliminate the possibility
that the observed decreased phosphorylation and activation
were somehow caused by a conformational change induced
by the point mutation itself, we examined the in vitro phos-
phorylation status and the ARF-dependent or PKC-depen-
dent activity of the palmitoylation-deficient PLD1 mutant
versus WT PLD1. As shown in Figure 8, C and D, the
C240S/C24 1S mutant was phosphorylated in vitro by PKC
Figure 6. Palmitoylation is required for CEM localization of PLD1
and its colocalization with caveolin-1 and the EGFR. (A) COS-7 cells
were transfected with control vector, WT PLD1, or C240S/C241S
mutant. After 24 h, the cells were starved and loaded with
[3H]palmitate (1 mCi/ml) for 5 h. Cell lysates (2 mg) were immu-
noprecipitated with anti-PLD antibody, and the resulting precipi-
tates were subjected to 8% SDS-PAGE and then transferred to a
nitrocellulose membrane. The PLD1 band was excised and its ra-
dioactivity monitored by Cerenkov counting. (B) CEMs were pre-
pared from quiescent COS-7 cells expressing WT PLD1 or C240S/
C241S mutant by sucrose density-gradient centrifugation. Twenty-
five microliters of each fraction was subjected to 6–16% gradient
SDS-PAGE followed by immunoblot analysis with anti-PLD, anti-
EGFR, anti-caveolin-1, or anti-Bip/GRP78 antibody. The localiza-
tions and the amounts of the EGFRs and caveolin-1 in WT-PLD1–
transfected cells and in mutant-transfected cells were identical. The
blots shown are representative of three separate results. (C) COS-7
cells were cotransfected with GFP-PLD1 WT or GFP-PLD1 C240S/
C241S and with RFP-caveolin-1. The cells were fixed, and GFP-
PLD1 and RFP-caveolin-1 were examined under a confocal micro-
scope. (D) COS-7 cells were cotransfected with GFP-PLD1 WT or
GFP-PLD1 C240S/C241S and with RFP-EGFR. The cells were fixed,
and GFP-PLD1 and RFP-EGFR were also examined by confocal
microscopy. (E) COS-7 cells were transfected with vector, WT PLD1,
or C240S/C241S mutant. After 48 h of expression, the cells were
harvested, fractionated by hypotonic buffer, and ultracentrifuged to
separate the cytosol and crude membrane fractions. The superna-
tant was designated cytosol (C) and kept, whereas the pellet con-
taining the membrane fraction (M) was resuspended in buffer of
volume equal to the supernatant. Equal volumes of the cytosol and
membrane fractions were analyzed by immunoblot analysis with
anti-PLD antibody.
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to the same extent as WT PLD1, and no differences were
detected in the ARF-dependent or PKC-dependent activity
of this mutant versus the WT. These results suggest that the
localization of PLD1 to the CEM is critical for the phosphor-
ylation and activation of PLD1 by PKC.
EGF-Induced Phosphorylation of PLD1 Occurs
Primarily in the Plasma Membrane of COS-7 Cells
Caveolin-1 is the defining protein component of caveolae
within the plasma membrane, but significant amounts of
caveolin-1 are known to exist in intracellular compartments,
such as the ER and the trans-Golgi network (Smart et al.,
1999). Liquid-ordered domains like caveolae can also form
within the Golgi apparatus and may play a role in the
biosynthetic trafficking of cholesterol from the ER to the
plasma membrane (Smart et al., 1999). Therefore, the CEM
fraction in Figures 5 and 6 may also contain membranes
derived from cytoplasmic organelles. To visualize the local-
ization of PLD1 phosphorylation in intact cells, we stained
phosphorylated PLD1 with phospho-PLD1 mAb after EGF
simulation. The GFP-PLD1 WT overexpressed in COS-7 cells
was generally present in the plasma membrane and in cy-
toplasmic vesicular structures, and after treatment with
EGF, phosphorylated PLD1 was found primarily in the
plasma membrane (Figure 9). Conversely, in C240S/C241S
mutant-transfected COS7 cells, phosphorylated PLD1 was
not detected in the plasma membrane. These results there-
fore indicate that PLD1 phosphorylation may occur in the
caveolae-like domains of the plasma membrane and not in
those of the cytoplasmic endomembranes and furthermore,
that palmitoylation of PLD1 contributes to EGF-dependent
phosphorylation of PLD1 in the plasma membrane.
The Localization of PLD1 to the CEM Is Required
for EGF-induced Raf-1 Translocation and ERK
Phosphorylation in the CEM
We next addressed the question of whether the palmitoyl-
ation and localization of PLD1 to the CEM are necessary for
the Raf-ERK pathway. COS-7 cells were transfected with
control vector, WT, or C240S/C241S mutant PLD1 and stim-
ulated with EGF for 0.5 min, and each CEM fraction in the
vector, WT-transfected, and C240S/C241S mutant-trans-
fected cells was obtained. Interestingly, the amount of Raf-1
in the CEM was rapidly increased by EGF treatment in the
WT-transfected cells but not in the vector or C240S/C241S
mutant-transfected cells (Figure 10). In addition, ERK phos-
phorylation in the CEM was also elevated by EGF treatment
only in the WT-transfected cells. These results demonstrate
that the palmitoylation-dependent localization of PLD1 to
the CEM contributes to the localized formation of PA and
that this has a critical function in the activation of the MAPK
cascade through Raf-1 translocation to the CEM.
DISCUSSION
PLD1 has been found to be expressed at various subcellular
locations, but the functions of and the regulatory mecha-
nisms involving PLD1 at each cellular location are not well
understood. Previously, we reported that PLD1 cofraction-
ated with caveolin-1, a marker for CEM (Kim et al., 1999).
However, the knowledge of the functional importance of the
correct CEM localization of PLD1 with respect to PLD1
regulation and its signaling pathway are limited. In this
study, for the first time, we present experimental evidence
that proves that the correct localization of PLD1 to the CEM
via palmitoylation is critical for PLD1 regulation and EGF
signaling.
The PKC-dependent regulatory mechanism of PLD has
been a central issue in PLD regulation studies (Exton, 1999).
However, the nature of the receptor-mediated stimulations
associated with the phosphorylation of PLD1 and the issue
of whether phosphorylation is essential for the PLD1 activity
induced by receptor stimulation remained to be determined.
Previously, we reported that PKC-mediated phosphoryla-
tion is required for PMA-induced PLD1 activation (Kim et
al., 1999). We also observed that PKC-mediated PLD1
phosphorylation is required for EGF-induced activation, be-
cause DN-PKC, which encodes a kinase-defective mutant
of PKC (K368R), inhibited EGF-induced PLD1 phosphory-
lation and activation (Figure 3, B and C). Surprisingly, DN-
PKC, which encodes a kinase-defective mutant of PKC
(K376R), enhanced EGF-induced PLD1 phosphorylation and
activation (Figure 3B and 3C). Previously, PKC isoforms 
and  were reported to have antagonistic effects on PLD
activity (Hornia et al., 1999). Thus, the translocation of PKC
to the CEM induced by EGF treatment may contribute to the
negative regulation of EGF-induced PLD1 activation. Al-
Figure 7. Complex formation of PLD1 with caveolin-1 and with
the EGFR in the CEM. COS-7 cells transfected with WT or C240S/
C241S mutant of PLD1 were incubated in the presence or absence of
100 nM of EGF for 0.5 min. The CEM fraction was prepared, and the
proteins were solubilized in an extraction buffer (10 mM Tris-HCl,
pH 7.4, 10 mM EDTA, 1% Nonidet P-40, 0.4% deoxycholate, 60 mM
-octylglucopyranoside, 0.5 mM phenylmethylsulfonylfluoride, 1
g/ml leupeptin, and 5 g/ml aprotinin). The sample was centri-
fuged at 150,000  g for 1 h, and the solubilized supernatant was
incubated with anti-PLD antibody precoupled to protein A agarose
resin. The immune complexes were subjected to 6–16% gradient
SDS-PAGE followed by immunoblot analysis with anti-PLD, anti-
EGFR, or anti-caveolin-1 antibody. The blots shown are representa-
tive of three separate results. I.P., immunoprecipitate.
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though the molecular mechanism of the involvement of
PKC on the regulation of EGF-induced PLD1 activation is
still unknown, in this report, we show that PKC and PKC,
which are activated via EGFR activation, antagonistically
regulate PLD1 by phosphorylation-dependent mechanisms.
Figure 9. EGF-induced phosphorylation of PLD1 occurs specifically
in the plasma membrane. COS-7 cells transfected with GFP-WT PLD1
were starved and then stimulated with 100 nM of EGF for 0.5 min. The
cells were fixed and stained with anti-phospho-PLD1 antibody, and
rhodamine-conjugated anti-mouse antibody was used as a secondary
antibody. GFP-PLD1 and phosphorylated PLD1 (Phospho-PLD1) were
examined under a confocal microscope. The data shown are represen-
tative of four separate experiments.
Figure 8. Palmitoylation of PLD1 is required for its phosphorylation
and activation by EGF. (A) COS-7 cells transfected with WT or C240S/
C241S mutant PLD1 were incubated in the absence or presence of 100
nM of EGF for 0.5 min. PLD1 was immunoprecipitated, and the im-
mune complex was subjected to immunoblot analysis with anti-phos-
pho-PLD1 or anti-PLD antibody. (B) COS-7 cells (2.5  105) were
transfected with vector alone, WT PLD1, or C240S/C241S mutant
PLD1. The cells were stimulated with 100 nM of EGF in the presence of
1.5% ethanol for 0.5 min, and the lipids were extracted to determine
PLD activity. The numbers indicate the amount of phosphatidyletha-
nol (PEt) formed after EGF stimulation. Data represent mean  SD
values of three independent experiments performed in duplicate. (C)
Lysates from WT or mutant PLD1-transfected COS-7 cells were immu-
noprecipitated (I.P.) with anti-PLD1 antibody, and the immune com-
plex was phosphorylated in vitro with PKC in the presence of PMA
and ATP at 37°C for 15 min and then immunoblotted with anti-
phospho-PLD1 antibody. (D) In vitro PLD activity was measured with
mixed lipid vesicles. Cell homogenates (0.5 g) were assayed for PLD
activity in the presence or absence of 1 M ARF/10 MGTPS or 10
nM PKC/100 nM PMA. The data shown are representative of three
separate experiments.
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The activation of PLD1 by EGF stimulation seems to be
composed of several intricate mechanisms. PLD1 can be
regulated by various activators, such as PKC, ARF, and Rho
family proteins (Exton, 1999). Although we have suggested
the involvement of phosphorylation in the EGF-induced
activation of PLD1 within the CEM, the precise role of the
phosphorylation in the activation process remains un-
known. The phosphorylation itself is not likely to increase
the catalytic activity directly, because the catalytic activity of
PLD1, activated by PKC in vitro, did not require ATP
(Hammond et al., 1997). Previously, Rac1 or Ras/Ral signal-
ing was reported to be required for the activation of PLD
after EGF stimulation (Hess et al., 1997; Voss et al., 1999), and
Rac1 and Ral A are known to stimulate PLD1 by direct
interaction (Hammond et al., 1997; Kim et al., 1998). There-
fore, the possibility exists that PKC phosphorylation facil-
itates the binding of PLD1 stimulators, such as the low-
molecular-weight G proteins, to PLD1.
Compartmentalization of PLD1 in the CEM has been re-
ported recently, but the important domain or motif required
for correct localization is not known. Lipid modification is
required or, at least, greatly facilitates the targeting of a
protein to the caveolae (Smart et al., 1999). The C-terminal
domain of caveolin-1 also undergoes palmitoylation at three
residues (Uittenbogaard and Smart, 2000). PLD1 has been
reported to be palmitoylated at cysteine240 and cysteine241,
which reside in the PH domain (Sugars et al., 1999). In the
present study, WT PLD1 is enriched in the CEM fraction
(Figure 5), colocalized with caveolin-1 (Figure 6C), and co-
immunoprecipitated with caveolin-1 (Figure 7). Previously,
we also reported the direct interaction of PLD1 with caveo-
lin-1 (Kim et al., 1999). Caveolin-1 is the structural compo-
nent of caveolae within the plasma membrane, but signifi-
cant amounts of caveolin-1 are known to exist in
intracellular compartments, such as the ER and the trans-
Golgi network (Smart et al., 1999) (Figure 6C). In Figure 9,
PKC-phosphorylated PLD1 was found primarily in the
plasma membrane, suggesting that WT PLD1 phosphoryla-
tion may occur in the caveolae-like domains of the plasma
membrane and not in those of the cytoplasmic endomem-
branes. Conversely, in C240S/C241S mutant-transfected
cells, phosphorylated PLD1 was not detected in the plasma
membrane. The palmitoylation-deficient mutant of PLD1
(C240S/C241S) was excluded from the CEM fraction (Figure
6B), and the C240S/C241S mutant could not be coimmuno-
precipitated with caveolin-1 in the CEM, although WT was
coimmunoprecipitated with caveolin-1. Therefore, palmi-
toylation of PLD1 contributes to EGF-dependent phosphor-
ylation of PLD1 in the plasma membrane and may be a
targeting signal to direct PLD1 to a specific plasma mem-
brane domain, the caveolae.
The PLD1 was found to be regulated by its interaction
with phosphatidylinositol 4,5-bisphosphate (PIP)2-contain-
ing membranes (Hammond et al., 1995). Therefore, there are
two possibilities for the localization signal in the PLD1. One
involves a hydrophobic interaction between the palmitate of
PLD1 and the lipid components of CEM, and the other an
interaction between the PLD1 and membrane PIP2. In the
present study, interestingly, the double mutant (C240S/
C241S) of the palmitoylation sites on PLD1 mislocalized
from the CEM to the non-CEM fraction, although the bind-
ing property of C240S/C241S mutant to PIP2 seemed to be
unchanged versus the WT protein (Figure 8D). However, a
substantial portion of C240S/C241S mutant was recovered
in the membrane fraction (Sugars et al., 1999) (Figure 6E).
Thus, these results raise the possibility that the key factor for
CEM localization of PLD1 is palmitoylation modification
and that the general factor of membrane localization is not
palmitoylation modification but other actions, such as inter-
actions with membrane lipid or proteins.
Because the palmitoylation/depalmitoylation process is
readily reversed by enzymatic machinery within the cells
(Camp and Hofmann, 1993), palmitoylation may represent a
means by which the function of PLD1 can be regulated. Our
results demonstrate the presence of PLD1 in two different
cellular compartments, i.e., the CEM and the non-CEM. WT
PLD1 in the non-CEM seemed to be a nonpalmitoylated
form and was not regulated by PKC. The molecular mech-
anisms of PLD1 palmitoylation/depalmitoylation, caused
by a putative palmitoyl transferase and a unknown cysteine
palmitoyl thioesterase, respectively, are unknown. Thus,
studies on the palmitoylation/depalmitoylation processes in
cells will contribute to the understanding of the regulatory
mechanism of PLD1.
Different results have been reported regarding localiza-
tion of EGFR in cells. On the basis of detergent-free mem-
brane fractionation experiments, as much as 40–60% of the
total pool of EGFR at the plasma membrane has been re-
ported to localize to caveolae in nonstimulated cells not
overexpressing the EGFR (Mineo et al., 1999). In A431 cells,
which overexpress the EGFR, similar detergent-free fraction-
ation experiments have shown that the majority of the EGFR
is localized within caveolin-enriched low-buoyant-density
membrane domains (Couet et al., 1997; Pike and Miller, 1998;
Waugh et al., 1999). Recently, Ringerike et al. (2002), using
immuno-electron microscopy, reported that 7% of the total
number of EGFRs at the plasma membrane are within
Figure 10. The localization of PLD1 to the CEM is required for
EGF-induced Raf-1 translocation to the CEM and ERK phosphory-
lation. COS-7 cells transfected with control vector, WT, or C240S/
C241S mutant of PLD1 were starved and then stimulated with 100
nM of EGF for 0.5 min. CEM fractions were prepared, and equal
amounts of proteins (5 g) were separated by gel electrophoresis
before immunoblotting with anti-Raf-1, anti-phospho-ERK, anti-
EGFR, anti-PLD, and anti-caveolin-1 antibody. The blots shown are
representative of three separate results.
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caveolae and 40% of EGFRs localizing to the plasma mem-
brane are within anti-PLAP patched rafts in nonstimulated
A431 cells. Therefore, it seems that the EGFR is within both
caveolae and raft. Couet et al. (1997) reported the coimmu-
noprecipitation of EGFR using anti-caveolin IgG and the
direct interaction of caveolin-1 with EGFR. Park et al. (2000)
also reported that EGFR was coimmunoprecipitated with
caveolin-1. In this study, we showed that PLD1 is cofrac-
tionated with caveolin-1 and EGFR (Figure 6B), coimmuno-
precipitated with caveolin-1 and EGFR (Figure 7), and colo-
calized with caveolin-1 and EGFR (Figure 6, C and D).
However, the palmitoylation-deficient mutant remained in
the non-CEM and could not form a molecular complex with
the EGFR and caveolin-1. Consequently, it was not receptive
to EGFR signaling and could not be phosphorylated or
activated by PKC. This finding demonstrates that the CEM
localization of PLD1 is required for complex formation with
the EGFR and caveolin-1, as well as for the regulation of
PLD1 by PKC.
Whereas the natures of the events occurring at the caveo-
lae within the plasma membrane remain unresolved, it is
clear that the activation of Raf-1 by growth factors requires
the translocation of Raf-1 from the cytoplasm to the plasma
membrane, where it is activated by interacting with GTP-
bound Ras (Mineo et al., 1997; Roy et al., 1997), by PKC
phosphorylation (Kolch et al., 1993; Carrol and May, 1994)
and by tyrosine kinases (Fabian et al., 1993; Marais et al.,
1995). It has also been reported that Raf-1 interacts with
phosphatidylserine and PA in vitro (Ghosh et al., 1996), and
it has been shown that mutations that disrupt Raf-PA inter-
actions prevent the recruitment of Raf-1 to membranes and
insulin-dependent MAPK phosphorylation (Rizzo et al.,
2000). We also found that the overexpression of PLD1 WT
but not of C240S/C241S mutant concurrently induced tran-
sient EGF-dependent Raf-1 translocation to the CEM and
ERK phosphorylation. These results demonstrate that tran-
sient translocation of Raf to the CEM and ERK phosphory-
lation by EGF are dependent on the localized regulation of
PLD1 within the CEM.
In conclusion, in this study, we demonstrate the molecular
mechanism and the importance of the CEM localization of
PLD1 in the EGF signaling pathway. A focus on the compo-
nents of caveolae will be a useful strategy in the search to
identify the molecular networks of PLD1 in signaling path-
ways.
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